APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
Walker BA et al. Nat Commun. 2015 Apr 23;6:6997. doi: 10.1038/ncomms7997.

Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1.
Fujiwara S et al. Exp Hematol Oncol. 2015 Apr 21;4:12. doi: 10.1186/s40164-015-0008-z. eCollection 2015.

Dutcher bodies in multiple myeloma are highly associated with translocation t(4;14) and IgA isotype.
Jiang N et al. Br J Haematol. 2015 Apr 24. doi: 10.1111/bjh.13457. [Epub ahead of print].

Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.
Villa NY et al. Blood. 2015 Apr 22. pii: blood-2014-07-587329. [Epub ahead of print].

Cytokine-induced apoptosis inhibitor 1 inhibits the growth and proliferation of multiple myeloma.
Wang X et al. Mol Med Rep. 2015 Apr 22. doi: 10.3892/mmr.2015.3656. [Epub ahead of print].

Cohort analysis of FISH testing of CD138+ cells in relapsed multiple myeloma: implications for prognosis and choice of therapy.
Smith D et al. Br J Haematol. 2015 Apr 21. doi: 10.1111/bjh.13446. [Epub ahead of print].

Targeting cullin-RING ligases for cancer treatment: rationales, advances and therapeutic implications.
Wu S et al. Cytotechnology. 2015 Apr 23. [Epub ahead of print].

Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myelomawith adverse prognosis.
Bustany S et al. J Hematol Oncol. 2015 Apr 23;8(1):40. [Epub ahead of print].

The use of animal models in multiple myeloma.
Libouban H. Morphologie. 2015 Apr 17. pii: S1286-0115(15)00022-3. doi: 10.1016/j.morpho.2015.01.003. [Epub ahead of print].

Generation and Characterization of a New Monoclonal Antibody Against CXCL4.
Gao J et al. Monoclon Antib Immunodiagn Immunother. 2015 Apr;34(2):110-5. doi: 10.1089/mab.2014.0050.

Anti-β2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
Zhang M et al. Oncotarget. 2015 Mar 31. [Epub ahead of print].

Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway.
Chen Y et al. Sci Rep. 2015 Apr 20;5:9925. doi: 10.1038/srep09925.

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
Guillerey C et al. J Clin Invest. 2015 Apr 20. pii: 77181. doi: 10.1172/JCI77181. [Epub ahead of print].

The proteasome inhibitor bortezomib induces testicular toxicity by upregulation of oxidative stress, AMP-activated protein kinase (AMPK) activation and deregulation of germ cell development in adult murine testis.
Li W et al. Toxicol Appl Pharmacol. 2015 Apr 15;285(2):98-109. doi: 10.1016/j.taap.2015.04.001. [Epub ahead of print].

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
Jeong JY et al. J Hematol Oncol. 2015 Apr 16;8(1):37. doi: 10.1186/s13045-015-0136-2.

The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies.
Dosani T et al. Blood Cancer J. 2015 Apr 17;5:e306. doi: 10.1038/bcj.2015.32.

Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway.
Bustany S et al. BMC Cancer. 2015 Apr 11;15:262. doi: 10.1186/s12885-015-1240-y.

Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data.
Sevcikova S et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Apr 16. doi: 10.5507/bp.2015.014. [Epub ahead of print].

Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins.
Liu L. J Pharm Sci. 2015 Apr 14. doi: 10.1002/jps.24444. [Epub ahead of print].

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
Sehgal K et al. Blood. 2015 Apr 13. pii: blood-2014-11-611426. [Epub ahead of print].

A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.
Paton-Hough J et al. Bone. 2015 Apr 11. pii: S8756-3282(15)00115-5. doi: 10.1016/j.bone.2015.04.004. [Epub ahead of print].

Myeloma cell-derived Runx2 promotes myeloma progression in bone.
Trotter TN et al. Blood. 2015 Apr 10. pii: blood-2014-12-613968. [Epub ahead of print].

Modulation of cereblon levels by anti-myeloma agents.
Díaz-Rodríguez E et al. Leuk Lymphoma. 2015 Apr 10:1-34. [Epub ahead of print].

Frequent down regulation of the tumor suppressor gene a20 in multiple myeloma.
Troppan K et al. PLoS One. 2015 Apr 9;10(4):e0123922. doi: 10.1371/journal.pone.0123922. eCollection 2015.

Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma.
Zhang Q et al. J Clin Pathol. 2015 Apr 8. pii: jclinpath-2014-202817. doi: 10.1136/jclinpath-2014-202817. [Epub ahead of print].

Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation.
Gu Z et al. Cancer Res. 2015 Apr 8. pii: canres.3804.2014. [Epub ahead of print].

Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15.
Wang X et al. Chem Biol Drug Des. 2015 Apr 9. doi: 10.1111/cbdd.12571. [Epub ahead of print].

In Silico Modeling-based Identification of GLUT4 Selective Inhibitors for Cancer Therapy.
Mishra RK et al. J Biol Chem. 2015 Apr 6. pii: jbc.M114.628826. [Epub ahead of print].

An Anti-B Cell Maturation Antigen Bispecific Antibody for Multiple Myeloma.
Ramadoss NS et al. J Am Chem Soc. 2015 Apr 15. [Epub ahead of print].

Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma.
Huang H et al. Blood Coagul Fibrinolysis. 2015 Mar 30. [Epub ahead of print].

Downregulation of Sprouty homolog 2 by microRNA-21 inhibits proliferation, metastasis and invasion, however promotes the apoptosis of multiple myeloma cells.
Wang JH et al. Mol Med Rep. 2015 Mar 30. doi: 10.3892/mmr.2015.3567. [Epub ahead of print].

Metabolic Profiling-based Data-mining for an Effective Chemical Combination to Induce Apoptosis of Cancer Cells.
Kumazoe M et al. Sci Rep. 2015 Mar 31;5:9474. doi: 10.1038/srep09474.

Small molecule MYC inhibitor conjugated to integrin-targeted nanoparticles extends survival in a mouse model of disseminated multiple myeloma.
Soodgupta D et al. Mol Cancer Ther. 2015 Mar 30. pii: molcanther.0774.2014. [Epub ahead of print].

Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
Dytfeld D et al. Br J Haematol. 2015 Mar 30. doi: 10.1111/bjh.13394. [Epub ahead of print].

The alteration and clinical significance of Th1/Th2/Th17/Treg cells in patients with multiple myeloma.
Feng P et al. Inflammation. 2015 Apr;38(2):705-9. doi: 10.1007/s10753-014-9980-4.